Improving cancer treatment with cyclotron produced radionuclides. Progress report

Technical Report · Mon Nov 01 04:00:00 EST 1993

DOI:https://doi.org/10.2172/10118877· OSTI ID:10118877

Larson, S M; Finn, R D

This report describes our continuing long term goal of promoting nuclear medicine applications by improving the scientific basis for tumor diagnosis, treatment and treatment follow-up based on the use of cyclotron produced radiotracers in oncology. The program includes 3 interactive components: Radiochemistry/Cyclotron; Pharmacology; and Immunology. An essential strategy is as follows: novel radionuclides and radiotracers developed in the Radiochemistry/Cyclotron section will be employed in the Pharmacology and Immunology sections during the next year. The development of novel radionuclides and tracers is of course useful in and of itself, but their utility is greatly enhanced by the interaction with the immunology and pharmacology components of the program.

• Research Organization: Memorial Sloan-Kettering Cancer Center, New York, NY (United States)
• Sponsoring Organization: USDOE, Washington, DC (United States)
• DOE Contract Number: FG02-86ER60407
• OSTI ID: 10118877
• Report Number(s): DOE/ER/60407--T2; ON: DE94006027; BR: HA0207010/KP0601000
• Country of Publication: United States
• Language: English

Related Subjects

38 RADIATION CHEMISTRY, RADIOCHEMISTRY, AND NUCLEAR CHEMISTRY
400703
550601
550604
62 RADIOLOGY AND NUCLEAR MEDICINE
CARBON 11
CHEMICAL PREPARATION
CYCLOTRONS
DOSIMETRY
FLUORINE 18
GALLIUM 66
IMMUNOGLOBULINS
IODINE 124
NUCLEAR MEDICINE
PATIENTS
POSITRON COMPUTED TOMOGRAPHY
PROGRESS REPORT
RADIOISOTOPE PRODUCTION
RADIOPHARMACEUTICALS
UNSEALED RADIONUCLIDES IN DIAGNOSTICS
UNSEALED RADIONUCLIDES IN THERAPY